Bicycle Therapeutics Plc Quick Ratio (BCYC) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Bicycle Therapeutics Plc  (NASDAQ: BCYC)

Bicycle Therapeutics Plc's Quick Ratio

BCYC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 10.71 above company average Quick Ratio.

Within Major Pharmaceutical Preparations industry 99 other companies have achieved higher Quick Ratio than Bicycle Therapeutics Plc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 414, from total ranking in the first quarter 2026 at 509.

Explain Quick Ratio?
How much Cash & cash equivalents BCYC´s has?
What are BCYC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BCYC Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -38.47 % -15.16 % -15.24 % 22.83 % 11.22 %
Y / Y Cash & cash equivalent Change -29.3 % -29.45 % -28.58 % -27.22 % -24.96 %
Quick Ratio MRQ 10.71 11.44 11.02 9.36 9.32
BCYC's Total Ranking # 414 # 509 # 549 # 564 # 409
Seq. Current Liabilities Change -2.56 % -14.21 % -17.75 % -10.51 % 34.36 %
Seq. Cash & cash equivalent Change -8.83 % -10.93 % -3.12 % -10.14 % -9.02 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 100
Healthcare Sector # 151
Overall Market # 431


Quick Ratio Statistics
High Average Low
15.79 9.57 4.71
(Sep 30 2024)   (Jun 30 2023)




Financial Statements
Bicycle Therapeutics Plc's Current Liabilities $ 48 Millions Visit BCYC's Balance sheet
Bicycle Therapeutics Plc's Cash & cash equivalent $ 510 Millions Visit BCYC's Balance sheet
Source of BCYC's Sales Visit BCYC's Sales by Geography


Cumulative Bicycle Therapeutics Plc's Quick Ratio

BCYC's Quick Ratio for the trailling 12 Months

BCYC Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -13.87 % 0.68 % 7.64 % 10.81 % 0.11 %
Y / Y Cash & cash equivalent TTM Growth -28.58 % -27.44 % -12.48 % 7.29 % 30.51 %
Quick Ratio TTM 10.53 10.13 10.68 11.2 12.7
Total Ranking TTM # 129 # 142 # 75 # 60 # 51
Seq. Current Liabilities TTM Growth -11.79 % -3.34 % -3.77 % 4.98 % 3.11 %
Seq. Cash & cash equivalent TTM Growth -8.27 % -8.37 % -8.26 % -7.38 % -6.81 %

Quick ratio ranking by company, industry and sector >> Back to BCYC Financial Strength Comparisons >> Go to Compare BCYC Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Bicycle Therapeutics Plc's average Cash & cash equivalent, this led to increase in in Bicycle Therapeutics Plc's Quick Ratio to 10.53, above BCYC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 410 other companies have achieved higher Quick Ratio than Bicycle Therapeutics Plc. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3254.

Explain Quick Ratio?
How much Cash & cash equivalents BCYC´s has?
What are BCYC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 411
Healthcare Sector # 832
Within the Market # 414


trailing twelve months Quick Ratio Statistics
High Average Low
14.05 9.25 6.06
(Mar 31 2025)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Crinetics Pharmaceuticals Inc   29.41 $ 2,350.275  Millions$ 79.915  Millions
Spyre Therapeutics Inc   28.48 $ 1,100.000  Millions$ 38.620  Millions
Curanex Pharmaceuticals Inc  28.17 $ 2.938  Millions$ 0.104  Millions
Onkure Therapeutics Inc   28.04 $ 186.284  Millions$ 6.643  Millions
Ligand Pharmaceuticals Incorporated  27.33 $ 1,277.438  Millions$ 46.736  Millions
Shattuck Labs Inc   26.94 $ 208.300  Millions$ 7.731  Millions
Cryoport inc   26.87 $ 785.860  Millions$ 29.244  Millions
Roivant Sciences Ltd   26.82 $ 7,607.076  Millions$ 283.603  Millions
Palvella Therapeutics Inc   26.23 $ 313.381  Millions$ 11.947  Millions
Upstream Bio Inc   26.16 $ 261.307  Millions$ 9.988  Millions
Rallybio Corporation  26.02 $ 92.800  Millions$ 3.567  Millions
Assembly Biosciences Inc   25.95 $ 608.475  Millions$ 23.445  Millions
Arbutus Biopharma Corp  25.84 $ 92.625  Millions$ 3.585  Millions
Immix Biopharma Inc   25.49 $ 238.715  Millions$ 9.364  Millions
Boundless Bio Inc   25.00 $ 194.230  Millions$ 7.768  Millions
Sionna Therapeutics Inc   24.88 $ 268.300  Millions$ 10.782  Millions
Prothena Corporation Public Limited Company  24.72 $ 288.193  Millions$ 11.658  Millions
Zenas Biopharma Inc   24.28 $ 1,597.761  Millions$ 65.818  Millions
Neuphoria Therapeutics Inc   23.89 $ 19.866  Millions$ 0.832  Millions
Innoviva Inc   23.77 $ 1,118.871  Millions$ 47.064  Millions
Pepgen Inc   23.51 $ 211.674  Millions$ 9.005  Millions
Kailera Therapeutics Inc   23.41 $ 1,958.240  Millions$ 83.651  Millions
Equillium Inc   23.07 $ 57.164  Millions$ 2.478  Millions
Relmada Therapeutics Inc  21.72 $ 217.731  Millions$ 10.023  Millions
Keros Therapeutics Inc   21.20 $ 257.606  Millions$ 12.153  Millions
Protagonist Therapeutics inc   21.05 $ 782.576  Millions$ 37.181  Millions
Stablecoin Development Corporation  20.76 $ 7.122  Millions$ 0.343  Millions
Rhythm Pharmaceuticals Inc   20.65 $ 596.183  Millions$ 28.868  Millions
Structure Therapeutics Inc   20.31 $ 1,342.700  Millions$ 66.113  Millions
Scynexis Inc   19.69 $ 114.696  Millions$ 5.825  Millions

Date modified: 2026-09-14T03:48:48+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.